CONCORDBIO Stock Overview
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CONCORDBIO from our risk checks.
Concord Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,660.05 |
| 52 Week High | ₹1,677.95 |
| 52 Week Low | ₹900.05 |
| Beta | 0 |
| 1 Month Change | 10.80% |
| 3 Month Change | 19.76% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 76.08% |
Recent News & Updates
Shareholder Returns
| CONCORDBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.2% | 2.3% | 2.6% |
| 1Y | n/a | 56.7% | 45.0% |
Return vs Industry: Insufficient data to determine how CONCORDBIO performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CONCORDBIO performed against the Indian Market.
Price Volatility
| CONCORDBIO volatility | |
|---|---|
| CONCORDBIO Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: CONCORDBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: CONCORDBIO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Ankur Vaid | www.concordbiotech.com |
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications.
Concord Biotech Limited Fundamentals Summary
| CONCORDBIO fundamental statistics | |
|---|---|
| Market cap | ₹173.67b |
| Earnings (TTM) | ₹3.05b |
| Revenue (TTM) | ₹9.71b |
57.0x
P/E Ratio17.9x
P/S RatioIs CONCORDBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CONCORDBIO income statement (TTM) | |
|---|---|
| Revenue | ₹9.71b |
| Cost of Revenue | ₹2.09b |
| Gross Profit | ₹7.62b |
| Other Expenses | ₹4.57b |
| Earnings | ₹3.05b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 29.11 |
| Gross Margin | 78.48% |
| Net Profit Margin | 31.38% |
| Debt/Equity Ratio | 1.7% |
How did CONCORDBIO perform over the long term?
See historical performance and comparison